Delta-9-Tetrahydrocannabinol

THC (Δ9-tetrahydrocannabinol) is the primary psychoactive cannabinoid in Cannabis sativa L., acting as a partial agonist at CB1 (Ki ≈1.4–3.1 nM) and CB2 cannabinoid receptors to modulate neurotransmitter release, pain signaling, nausea, and appetite. Pharmaceutical THC formulations (dronabinol, nabilone) have demonstrated clinically meaningful reductions in chemotherapy-induced nausea and vomiting and cancer-related pain, with bioavailability reaching 10–30% via inhalation versus approximately 6% via oral administration.

Origin & History

Delta-9-tetrahydrocannabinol (THC) is the primary psychoactive cannabinoid synthesized within the trichomes of Cannabis sativa L., a plant indigenous to Central and South Asia but now cultivated globally across temperate and tropical regions. High-THC chemotype I strains are selectively bred to yield 15–22% THC (dry weight) in the flower, while chemotype II balanced strains yield 5–10% THC alongside comparable CBD concentrations. Modern pharmaceutical-grade THC is derived via solvent extraction methods including microwave-assisted extraction (MAE) and supercritical fluid extraction (SFE), yielding concentrations of 0–73.1% (w/w) in extracts.

Historical & Cultural Context

Cannabis sativa has been documented in Chinese pharmacopoeia as far back as 2700 BCE, with the Pen Ts'ao Ching attributed to Emperor Shennong describing its use for pain, rheumatism, and digestive complaints. In Ayurvedic medicine, cannabis preparations ('bhang', 'charas') were classified as analgesic and anxiolytic agents, used in ceremonial, medicinal, and culinary contexts across the Indian subcontinent for over two millennia. Arabic physicians of the medieval Islamic Golden Age, including Ibn Sina (Avicenna), documented cannabis resin for headache and earache in the Canon of Medicine (1025 CE). The isolation of THC as the primary psychoactive constituent was achieved by Raphael Mechoulam and Yechiel Gaoni at the Hebrew University of Jerusalem in 1964, marking the beginning of modern cannabinoid pharmacology and ultimately leading to the discovery of the endocannabinoid system in the 1990s.

Health Benefits

- **Pain Relief (Analgesia)**: THC engages CB1 receptors in the central and peripheral nervous system, inhibiting nociceptive neurotransmitter release; this mechanism underlies its use in neuropathic, cancer-related, and inflammatory pain conditions documented in clinical and preclinical studies.
- **Antiemetic Effects**: CB1 receptor agonism in the dorsal vagal complex and chemoreceptor trigger zone suppresses emetic signaling; dronabinol (synthetic THC) is FDA-approved for chemotherapy-induced nausea and vomiting refractory to conventional antiemetics.
- **Appetite Stimulation**: THC activates hypothalamic CB1 receptors and orexigenic pathways to increase appetite and caloric intake; it is approved as dronabinol for anorexia in HIV/AIDS wasting syndrome, where clinical trials showed significant weight stabilization.
- **Neuroprotection**: At concentrations of approximately 3 µM, THC has been shown in preclinical models to block NMDA receptor-induced neuronal apoptosis and reduce reactive oxygen species (ROS), suggesting a neuroprotective role in excitotoxic conditions, though human data remain limited.
- **Anti-inflammatory Activity**: THC modulates CB2 receptor signaling on immune cells to suppress pro-inflammatory cytokine release (e.g., TNF-α, IL-6) and may reduce neuroinflammation; this pathway is active in both CNS and peripheral tissues.
- **Muscle Spasticity Reduction**: In multiple sclerosis, nabiximols (THC:CBD 1:1 oromucosal spray) has demonstrated statistically significant reductions in patient-reported spasticity scores in randomized controlled trials, mediated through combined CB1 and CB2 modulation.
- **Intraocular Pressure Reduction**: THC reduces intraocular pressure through CB1 receptor-mediated vasodilation and reduced aqueous humor production, a property documented since the 1970s and relevant to glaucoma management, though short duration of action limits clinical utility.

How It Works

THC acts as a partial agonist at G-protein-coupled cannabinoid receptors CB1 (Ki ≈1.4–3.1 nM) and CB2 (Ki ≈0.015–1.2 nM), mimicking endogenous cannabinoids such as anandamide (AEA) and 2-arachidonoylglycerol (2-AG) to inhibit adenylyl cyclase, reduce cAMP levels, and suppress voltage-gated calcium channels while activating inwardly rectifying potassium channels, collectively dampening neuronal excitability and neurotransmitter release. Its high lipophilicity (logP ≈7) enables rapid crossing of the blood-brain barrier and extensive sequestration in adipose tissue, with a volume of distribution of 3.4–32 L/kg. At 0.1–100 µM, THC has been shown in preclinical pancreatic islet models to upregulate Pdx1 and Glut2 expression, enhancing glucose-stimulated insulin secretion, while at 3 µM it attenuates NMDA receptor-mediated excitotoxicity and reduces mitochondrial ROS generation. Acid precursor Δ9-THCA exhibits substantially lower CB receptor affinity (CB1 Ki ≈1.8–4.5; CB2 Ki ≈30) and requires decarboxylation to active THC through heat or prolonged storage.

Scientific Research

The clinical evidence base for THC is heterogeneous: FDA-approved pharmaceutical forms (dronabinol, nabilone) are supported by multiple randomized controlled trials for chemotherapy-induced nausea and HIV-related anorexia, providing moderate-to-strong evidence for these specific indications. For pain, systematic reviews and meta-analyses of cannabis-based medicines (CBMs) including THC-dominant products suggest modest analgesic benefit in neuropathic and cancer pain, but effect sizes are generally small-to-moderate and studies vary substantially in THC dose, delivery route, and patient population. Preclinical mechanistic data are robust, with well-characterized receptor binding kinetics and pharmacokinetic parameters (e.g., rectal bioavailability ~13.5%, peak plasma 1.1–4.1 ng/mL at 2.5–5 mg doses), though translation to standardized human dosing protocols remains incomplete. Significant gaps exist in large-scale RCTs for conditions such as glaucoma, neurodegeneration, and metabolic disease, where evidence remains largely preclinical or anecdotal.

Clinical Summary

Pharmaceutical THC (dronabinol) received FDA approval based on controlled trials demonstrating superiority over placebo in reducing chemotherapy-induced nausea and vomiting frequency, and in improving appetite and stabilizing weight in AIDS-related anorexia/cachexia, though effect sizes vary across trials. Nabiximols (Sativex, 1:1 THC:CBD oromucosal spray) completed multiple Phase III RCTs in multiple sclerosis spasticity, showing statistically significant improvements on the Numerical Rating Scale for spasticity versus placebo (mean difference approximately 0.5–1.2 points on an 11-point scale). Pain studies using inhaled or oral THC-dominant preparations report analgesic effects in neuropathic pain cohorts, but methodological heterogeneity, small sample sizes (often n<100), and short follow-up durations limit confidence in generalizability. Overall, clinical confidence is strong for antiemetic and appetite indications via approved pharmaceuticals, moderate for spasticity and neuropathic pain, and preliminary for most other proposed applications.

Nutritional Profile

THC is a pure bioactive compound (C₂₁H₃₀O₂, molecular weight 314.46 g/mol) rather than a nutritional ingredient, and thus lacks conventional macronutrient or micronutrient profiles. As a highly lipophilic terpenophenolic compound (logP ≈7), it is soluble in oils and organic solvents but poorly soluble in water, which governs its absorption—oral bioavailability is enhanced by co-administration with high-fat meals that promote lymphatic uptake. Cannabis flower contains co-occurring phytochemicals including monoterpenoids (myrcene, limonene, pinene), sesquiterpenoids (caryophyllene, humulene), flavonoids (cannflavin A, B), and other cannabinoids (CBD, CBG, CBC, THCV) that modulate THC pharmacodynamics via the proposed 'entourage effect.' In whole-plant preparations, dried cannabis flower chemotype I provides 15–22% THC (dry weight), while extracts can concentrate THC to 0–73.1% (w/w) depending on extraction method and starting material.

Preparation & Dosage

- **Oral Capsules (Dronabinol/Marinol)**: 2.5–10 mg per dose, 1–2 times daily; FDA-approved starting dose for nausea is 5 mg/m² 1–3 hours before chemotherapy; bioavailability ~6%, onset 30–120 minutes.
- **Oromucosal Spray (Nabiximols/Sativex, 1:1 THC:CBD)**: Each actuation delivers 2.7 mg THC + 2.5 mg CBD; typical therapeutic dose 8–12 sprays/day (titrated); onset 15–40 minutes.
- **Inhaled Vapor**: 1–5 mg THC per inhalation from vaporized cannabis flower or concentrate; bioavailability 10–30%; peak plasma concentration within 3–10 minutes; used in clinical settings for acute pain and nausea.
- **Rectal Suppositories**: 2.5–15 mg THC per suppository; bioavailability ~13.5% (approximately 2-fold greater than oral); peak plasma at 2–8 hours; no blood accumulation observed with daily 10–15 mg dosing in clinical observation.
- **Cannabis Oils (Oral)**: Δ9-THC 0–4.6% (w/v) in carrier oil; dose varies by product concentration; sublingual absorption faster than gastrointestinal; no standardized clinical dose established for supplement use.
- **Standardization**: Pharmaceutical-grade products are standardized to exact THC content; medicinal cannabis flower is classified by chemotype (I: >0.3% THC, II: balanced THC/CBD) with batch-level certificate of analysis required in regulated markets.
- **Timing**: For nausea, dosing 1–3 hours before chemotherapy is standard; for pain/sleep, evening dosing reduces daytime psychoactive burden.

Synergy & Pairings

THC demonstrates well-documented pharmacodynamic synergy with cannabidiol (CBD), which acts as a negative allosteric modulator at CB1 receptors, attenuating THC-induced anxiety, tachycardia, and psychotomimetic effects while potentially enhancing analgesic and anti-inflammatory outcomes—this combination is the basis of the clinically approved nabiximols formulation. Co-administration with terpenoids such as myrcene (a monoterpene in cannabis) is hypothesized to potentiate sedation and analgesia through complementary GABAergic and CB1 mechanisms, while β-caryophyllene may enhance anti-inflammatory activity via CB2 agonism, collectively forming the basis of the 'entourage effect' proposed by Russo (2011). THC combined with opioid analgesics has shown opioid-sparing potential in clinical pain studies, where sub-analgesic THC doses shift the opioid dose-response curve, though this combination requires careful clinical supervision due to additive CNS depression risk.

Safety & Interactions

At therapeutic doses, THC commonly produces dose-dependent psychoactive effects including euphoria, altered time perception, impaired short-term memory, increased heart rate (tachycardia), and dry mouth via CB1 agonism; at higher doses, anxiety, paranoia, dizziness, and psychotomimetic effects can occur, particularly in individuals naive to cannabinoids or with predisposition to psychiatric conditions. THC is metabolized primarily by hepatic CYP2C9 and CYP3A4 enzymes to the active metabolite 11-hydroxy-THC and then to inactive 11-nor-9-carboxy-THC; it may interact with CNS depressants (additive sedation), anticoagulants such as warfarin (CYP2C9 inhibition increasing bleeding risk), and drugs with narrow therapeutic indices metabolized by CYP3A4. THC is contraindicated in individuals with a personal or strong family history of psychosis or schizophrenia, in pregnancy and lactation (crosses placenta and is excreted in breast milk with documented fetal neurodevelopmental risk), and in adolescents due to evidence of adverse effects on developing neural circuits. Adipose accumulation with chronic use can result in prolonged detection in urine (up to 30 days in heavy users) and should be considered in occupational and legal contexts; no absolute maximum safe dose is universally established, but pharmaceutical formulations cap approved doses at 20 mg/day dronabinol for most indications.